833-60-3 Usage
Molecular Structure
2-(4-fluorophenyl)-2H-1,2,3-triazole-4-carboxylic acid consists of a triazole ring and a carboxylic acid functional group.
Functional Groups
The compound contains a triazole ring and a carboxylic acid functional group.
Fluorophenyl Group
The presence of the 4-fluorophenyl group contributes to the compound's potential as a pharmacophore, making it valuable for drug development.
Versatility
The carboxylic acid group allows for further modification and functionalization of the compound, making it useful for various applications in chemical and pharmaceutical research.
Usage
The compound is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of bioactive compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 833-60-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 8,3 and 3 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 833-60:
(5*8)+(4*3)+(3*3)+(2*6)+(1*0)=73
73 % 10 = 3
So 833-60-3 is a valid CAS Registry Number.
833-60-3Relevant academic research and scientific papers
SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS
-
Page/Page column 161, (2021/05/21)
The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.
IAP BIR domain binding compounds
-
Page/Page column 174; 175, (2016/04/05)
A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.
